Anixa Biosciences and MolGenie Announce that their COVID-19 Compounds are Expected to be Effective Against the Omicron Variant

SAN JOSE, Calif. and STUTTGART, Germany: SAN JOSE, Calif. and STUTTGART, Germany, Dec. 7, 2021 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, today announced the results of a genomic variant analysis done with its partner, MolGenie,...

Click to view original post